INZY Inozyme Pharma Inc
Price (delayed)
$0.9264
Market cap
$59.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.62
Enterprise value
$84.99M
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through the company's in-depth understanding of the biological pathways involved in
Highlights
The quick ratio has plunged by 74% YoY and by 53% from the previous quarter
The equity has dropped by 59% year-on-year and by 30% since the previous quarter
Key stats
What are the main financial stats of INZY
Market
Valuations
Earnings
Shares outstanding
64.24M
Market cap
$59.51M
Enterprise value
$84.99M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.03
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$104.03M
Net income
-$102.02M
EBIT
-$96.47M
EBITDA
-$95.16M
Free cash flow
-$91.97M
Per share
Balance sheet
Liquidity
EPS
-$1.62
EPS diluted
-$1.62
Free cash flow per share
-$1.46
Book value per share
$0.9
Revenue per share
$0
TBVPS
$1.96
Total assets
$123.18M
Total liabilities
$65.36M
Debt
$46.87M
Equity
$57.83M
Working capital
$86.78M
Debt to equity
0.81
Current ratio
3.56
Quick ratio
3.35
Net debt/EBITDA
-0.27
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-68.1%
Return on equity
-115.3%
Return on invested capital
-61.9%
Return on capital employed
-108%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INZY stock price
How has the Inozyme Pharma stock price performed over time
Intraday
6.48%
1 week
-3.47%
1 month
-22.8%
1 year
-86.63%
YTD
-66.56%
QTD
1.8%
Financial performance
How have Inozyme Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$104.03M
Net income
-$102.02M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 43% YoY and by 6% QoQ
INZY's operating income is down by 38% year-on-year and by 4.4% since the previous quarter
Growth
What is Inozyme Pharma's growth rate over time
Valuation
What is Inozyme Pharma stock price valuation
P/E
N/A
P/B
1.03
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
INZY's EPS is down by 18% year-on-year and by 3.8% since the previous quarter
The price to book (P/B) is 72% lower than the last 4 quarters average of 3.5 and 58% lower than the 5-year quarterly average of 2.3
The equity has dropped by 59% year-on-year and by 30% since the previous quarter
Efficiency
How efficient is Inozyme Pharma business performance
INZY's ROE has dropped by 106% year-on-year and by 30% since the previous quarter
The company's return on assets has shrunk by 67% YoY and by 19% QoQ
The company's return on invested capital fell by 41% YoY and by 20% QoQ
Dividends
What is INZY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INZY.
Financial health
How did Inozyme Pharma financials performed over time
Inozyme Pharma's total assets is 88% higher than its total liabilities
The quick ratio has plunged by 74% YoY and by 53% from the previous quarter
Inozyme Pharma's current ratio has plunged by 73% YoY and by 54% from the previous quarter
The company's debt is 19% lower than its equity
The debt to equity has soared by 145% YoY and by 42% from the previous quarter
The equity has dropped by 59% year-on-year and by 30% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.